That’s how Dr. Dane J. Dickson came to see the need for a new approach to personalized medicine. In early 2015, Dr. Dickson stepped away from Medicare and started the nonprofit organization MED-C, with the goal to build the needed collaborative product from the ground up that would fix the most pressing issues creating the disconnect that the nation was facing.
Just 18 months later, these efforts will culminate with the launch of a groundbreaking next-generation sequencing (NGS) registry, a landmark event toward closing these disconnects and dramatically propelling personalized medicine.
Our highest priority is enabling more effective cancer treatments to prolong the life of every patient. As MED-C collaborates with each part of the health care system, cancer knowledge will increase, research will accelerate and patients will be provided with more personalized care.
MED-C will ensure that physicians have real-time access to an accumulated database of information and research so they can provide more effective, personalized treatment to every patient. And physicians will provide information about the clinical outcomes of their patients that will enrich the database for future users.
Insurers will pay laboratories to conduct the enhanced, standardized, genetic-level testing outlined by MED-C’s protocols. Each individual test will generate many gigabytes of data and assist medical professionals to prescribe more effective treatment for their patients the first time, thus, significantly reducing costs for payors and patients.
Laboratories will carry out testing of patients and provide the standardized raw data for MED-C’s NGS registry. Rapid advances in technology allow labs to carry out genetic-level testing that’s much more robust than even a few years ago.
Pharmaceutical companies will be better able to initiate research toward development of more effective drugs as the registry grows in size. Additionally, they will become more efficient in organizing the clinical trials needed to bring those drugs to market, a process that can cost hundreds of millions of dollars.
The Food and Drug Administration will be able to more effectively monitor and oversee the testing process to better ensure that new drugs are ready for public usage. And government payors such as Medicare and Medicaid will save billions of dollars of taxpayers’ money.